Literature DB >> 20655780

Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I.

Patricia I Dickson1, Stephen Hanson, Michael F McEntee, Charles H Vite, Carole A Vogler, Anton Mlikotic, Agnes H Chen, Katherine P Ponder, Mark E Haskins, Brigette L Tippin, Steven Q Le, Merry B Passage, Catalina Guerra, Ashley Dierenfeld, Jackie Jens, Elizabeth Snella, Shih-Hsin Kan, N Matthew Ellinwood.   

Abstract

Enzyme replacement therapy (ERT) with intravenous recombinant human alpha-l-iduronidase (IV rhIDU) is a treatment for patients with mucopolysaccharidosis I (MPS I). Spinal cord compression develops in MPS I patients due in part to dural and leptomeningeal thickening from accumulated glycosaminoglycans (GAG). We tested long-term and every 3-month intrathecal (IT) and weekly IV rhIDU in MPS I dogs age 12-15months (Adult) and MPS I pups age 2-23days (Early) to determine whether spinal cord compression could be reversed, stabilized, or prevented. Five treatment groups of MPS I dogs were evaluated (n=4 per group): IT+IV Adult, IV Adult, IT + IV Early, 0.58mg/kg IV Early and 1.57mg/kg IV Early. IT + IV rhIDU (Adult and Early) led to very high iduronidase levels in cervical, thoracic, and lumber spinal meninges (3600-29,000% of normal), while IV rhIDU alone (Adult and Early) led to levels that were 8.2-176% of normal. GAG storage was significantly reduced from untreated levels in spinal meninges of IT + IV Early (p<.001), IT+IV Adult (p=.001), 0.58mg/kg IV Early (p=.002) and 1.57mg/kg IV Early (p<.001) treatment groups. Treatment of dogs shortly after birth with IT+IV rhIDU (IT + IV Early) led to normal to near-normal GAG levels in the meninges and histologic absence of storage vacuoles. Lysosomal storage was reduced in spinal anterior horn cells in 1.57mg/kg IV Early and IT + IV Early animals. All dogs in IT + IV Adult and IV Adult groups had compression of their spinal cord at 12-15months of age determined by magnetic resonance imaging and was due to protrusion of spinal disks into the canal. Cord compression developed in 3 of 4 dogs in the 0.58mg/kg IV Early group; 2 of 3 dogs in the IT + IV Early group; and 0 of 4 dogs in the 1.57mg/kg IV Early group by 12-18months of age. IT + IV rhIDU was more effective than IV rhIDU alone for treatment of meningeal storage, and it prevented meningeal GAG accumulation when begun early. High-dose IV rhIDU from birth (1.57mg/kg weekly) appeared to prevent cord compression due to protrusion of spinal disks.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20655780      PMCID: PMC2950221          DOI: 10.1016/j.ymgme.2010.06.020

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  21 in total

Review 1.  Multilevel myelopathy in Maroteaux-Lamy syndrome and review of the literature.

Authors:  Melike Mut; Ayşenur Cila; Kubilay Varli; Nejat Akalan
Journal:  Clin Neurol Neurosurg       Date:  2005-04       Impact factor: 1.876

2.  A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years.

Authors:  Monica Sifuentes; Robin Doroshow; Richard Hoft; Greg Mason; Irwin Walot; Michael Diament; Susan Okazaki; Kenneth Huff; Gerald F Cox; Stuart J Swiedler; Emil D Kakkis
Journal:  Mol Genet Metab       Date:  2006-09-29       Impact factor: 4.797

3.  Cervical cord compression in mucopolysaccharidosis.

Authors:  P Kennedy; M Swash; M F Dean
Journal:  Dev Med Child Neurol       Date:  1973-04       Impact factor: 5.449

4.  Cervical myelopathy due to dural compression in mucopolysaccharidosis.

Authors:  H H Kaufman; H S Rosenberg; C I Scott; Y Y Lee; J L Pruessner; I J Butler
Journal:  Surg Neurol       Date:  1982-06

5.  Long-term outcomes of adaptive functions for children with mucopolysaccharidosis I (Hurler syndrome) treated with hematopoietic stem cell transplantation.

Authors:  Kendra J Bjoraker; Kathleen Delaney; Charles Peters; William Krivit; Elsa G Shapiro
Journal:  J Dev Behav Pediatr       Date:  2006-08       Impact factor: 2.225

6.  Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid.

Authors:  Patricia Dickson; Michael McEntee; Carole Vogler; Steven Le; Beth Levy; Maryn Peinovich; Stephen Hanson; Merry Passage; Emil Kakkis
Journal:  Mol Genet Metab       Date:  2007-02-26       Impact factor: 4.797

7.  The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I.

Authors:  Gregory M Pastores; Pamela Arn; Michael Beck; Joe T R Clarke; Nathalie Guffon; Paige Kaplan; Joseph Muenzer; Denise Y J Norato; Elsa Shapiro; Janet Thomas; David Viskochil; J Edmond Wraith
Journal:  Mol Genet Metab       Date:  2007-03-02       Impact factor: 4.797

8.  Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I.

Authors:  E D Kakkis; M F McEntee; A Schmidtchen; E F Neufeld; D A Ward; R E Gompf; S Kania; C Bedolla; S L Chien; R M Shull
Journal:  Biochem Mol Med       Date:  1996-08

9.  Architecture of the canine IDUA gene and mutation underlying canine mucopolysaccharidosis I.

Authors:  K P Menon; P T Tieu; E F Neufeld
Journal:  Genomics       Date:  1992-11       Impact factor: 5.736

10.  Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I.

Authors:  E Kakkis; M McEntee; C Vogler; S Le; B Levy; P Belichenko; W Mobley; P Dickson; S Hanson; M Passage
Journal:  Mol Genet Metab       Date:  2004 Sep-Oct       Impact factor: 4.797

View more
  24 in total

1.  Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I.

Authors:  Christian Hinderer; Peter Bell; Brittney L Gurda; Qiang Wang; Jean-Pierre Louboutin; Yanqing Zhu; Jessica Bagel; Patricia O'Donnell; Tracey Sikora; Therese Ruane; Ping Wang; Mark E Haskins; James M Wilson
Journal:  Mol Ther       Date:  2014-07-16       Impact factor: 11.454

2.  Intra-articular enzyme replacement therapy with rhIDUA is safe, well-tolerated, and reduces articular GAG storage in the canine model of mucopolysaccharidosis type I.

Authors:  Raymond Y Wang; Afshin Aminian; Michael F McEntee; Shih-Hsin Kan; Calogera M Simonaro; William C Lamanna; Roger Lawrence; N Matthew Ellinwood; Catalina Guerra; Steven Q Le; Patricia I Dickson; Jeffrey D Esko
Journal:  Mol Genet Metab       Date:  2014-06-06       Impact factor: 4.797

3.  Biodistribution and pharmacodynamics of recombinant human alpha-L-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations.

Authors:  Charles H Vite; Ping Wang; Reema T Patel; Raquel M Walton; Steven U Walkley; Rani S Sellers; N Matthew Ellinwood; Alphonsus S Cheng; Joleen T White; Charles A O'Neill; Mark Haskins
Journal:  Mol Genet Metab       Date:  2011-03-21       Impact factor: 4.797

4.  Long-term nonsense suppression therapy moderates MPS I-H disease progression.

Authors:  Gwen Gunn; Yanying Dai; Ming Du; Valery Belakhov; Jeyakumar Kandasamy; Trenton R Schoeb; Timor Baasov; David M Bedwell; Kim M Keeling
Journal:  Mol Genet Metab       Date:  2013-12-17       Impact factor: 4.797

5.  Abnormal epiphyseal development in a feline model of Sandhoff disease.

Authors:  Margaret A McNulty; Patricia B Prevatt; Elizabeth R Nussbaum; Ashley N Randle; Aime K Johnson; Judith A Hudson; Heather L Gray-Edwards; Miguel Sena-Esteves; Douglas R Martin; Cathy S Carlson
Journal:  J Orthop Res       Date:  2020-07-29       Impact factor: 3.494

6.  Glycosaminoglycan storage in neuroanatomical regions of mucopolysaccharidosis I dogs following intrathecal recombinant human iduronidase.

Authors:  Agnes Chen; Carole Vogler; Michael McEntee; Stephen Hanson; N Matthew Ellinwood; Jackie Jens; Elizabeth Snella; Merry Passage; Steven Le; Catalina Guerra; Patricia Dickson
Journal:  APMIS       Date:  2011-05-14       Impact factor: 3.205

7.  Features of brain MRI in dogs with treated and untreated mucopolysaccharidosis type I.

Authors:  Charles H Vite; Igor Nestrasil; Anton Mlikotic; Jackie K Jens; Elizabeth M Snella; William Gross; Elsa G Shapiro; Victor Kovac; James M Provenzale; Steven Chen; Steven Q Le; Shih-hsin Kan; Shida Banakar; Raymond Y Wang; Mark E Haskins; N Matthew Ellinwood; Patricia I Dickson
Journal:  Comp Med       Date:  2013-04       Impact factor: 0.982

8.  Effects of neonatal enzyme replacement therapy and simvastatin treatment on cervical spine disease in mucopolysaccharidosis I dogs.

Authors:  Joseph A Chiaro; Patricia O'Donnell; Eileen M Shore; Neil R Malhotra; Katherine P Ponder; Mark E Haskins; Lachlan J Smith
Journal:  J Bone Miner Res       Date:  2014-12       Impact factor: 6.741

Review 9.  Pathogenesis and treatment of spine disease in the mucopolysaccharidoses.

Authors:  Sun H Peck; Margret L Casal; Neil R Malhotra; Can Ficicioglu; Lachlan J Smith
Journal:  Mol Genet Metab       Date:  2016-06-04       Impact factor: 4.797

10.  Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I.

Authors:  Patricia I Dickson; Ilkka Kaitila; Paul Harmatz; Anton Mlikotic; Agnes H Chen; Alla Victoroff; Merry B Passage; Jacqueline Madden; Steven Q Le; David E Naylor
Journal:  Mol Genet Metab       Date:  2015-07-26       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.